David Henner, DO
Nephrology · Pittsfield, MANPI 1487612032
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 68.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $26,701 and has fallen 88.8% since, to $3,000 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $1084.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65K
- Outset Medical Inc$30K
- Travere Therapeutics, Inc.$75
Across 9 payments — averaging $2757.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$25K
What the payments were for
- Consulting fees$44,64947%
- Speaking & faculty fees$39,30042%
- Travel & lodging$8,4759%
- Food & beverage$1,8952%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 55 | $64,614 |
| Outset Medical Inc | 31 | $29,631 |
| Travere Therapeutics, Inc. | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,320 in reported general payments places this provider in the 90th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 13 | $37,280 |
| FarxigaDapagliflozin Propanediol | 32 | $30,266 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $5,691 |
| Calcium Acetate | 42 | $1,767 |
| Sevelamer Carbonate | 28 | $1,560 |
| Torsemide | 94 | $1,226 |
| Chlorthalidone | 49 | $627 |
| Losartan Potassium | 63 | $524 |
| Lisinopril | 50 | $427 |
| Labetalol Hcl | 13 | $419 |
| Calcitriol | 22 | $402 |
| Metoprolol Succinate | 17 | $340 |
| Rosuvastatin Calcium | 20 | $318 |
| Amlodipine Besylate | 37 | $195 |
| Clonidine Hcl | 19 | $101 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Pittsfield
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
- Joshua HundertDorchester$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.